S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ruling halts oil exports from Iraq's Kurdish area via Turkey
The gold catalyst we’ve waited for (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Finnish leadership condemns attack on veteran lawmaker
Buy THIS stock before Taiwan is attacked (Ad)
Challenger wins close race to lead United Auto Workers union
Canada pledges Great Lakes funding after Trudeau-Biden talks
Free Stock Analysis Report: Invest Smarter With Powerful Data (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ruling halts oil exports from Iraq's Kurdish area via Turkey
The gold catalyst we’ve waited for (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Finnish leadership condemns attack on veteran lawmaker
Buy THIS stock before Taiwan is attacked (Ad)
Challenger wins close race to lead United Auto Workers union
Canada pledges Great Lakes funding after Trudeau-Biden talks
Free Stock Analysis Report: Invest Smarter With Powerful Data (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ruling halts oil exports from Iraq's Kurdish area via Turkey
The gold catalyst we’ve waited for (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Finnish leadership condemns attack on veteran lawmaker
Buy THIS stock before Taiwan is attacked (Ad)
Challenger wins close race to lead United Auto Workers union
Canada pledges Great Lakes funding after Trudeau-Biden talks
Free Stock Analysis Report: Invest Smarter With Powerful Data (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ruling halts oil exports from Iraq's Kurdish area via Turkey
The gold catalyst we’ve waited for (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Finnish leadership condemns attack on veteran lawmaker
Buy THIS stock before Taiwan is attacked (Ad)
Challenger wins close race to lead United Auto Workers union
Canada pledges Great Lakes funding after Trudeau-Biden talks
Free Stock Analysis Report: Invest Smarter With Powerful Data (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Technical issues at Lufthansa cause delays in Frankfurt
NASDAQ:SRNE

Sorrento Therapeutics - SRNE Stock Forecast, Price & News

$0.34
0.00 (0.00%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.32
▼
$0.36
50-Day Range
$0.17
▼
$1.19
52-Week Range
$0.16
▼
$3.09
Volume
1.71 million shs
Average Volume
52.69 million shs
Market Capitalization
$160.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

Sorrento Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
2,547.1% Upside
$9.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.05
Upright™ Environmental Score
News Sentiment
-0.32mentions of Sorrento Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.82) to ($0.74) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

753rd out of 1,005 stocks

Biological Products, Except Diagnostic Industry

129th out of 168 stocks

See Top Rated MarketRank™ Stocks Here

SRNE stock logo

About Sorrento Therapeutics (NASDAQ:SRNE) Stock

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Receive SRNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRNE Stock News Headlines

March 21, 2023 | wsj.com
Sorrento Therapeutics Opponent Loses Chapter 11 Committee Seat
March 20, 2023 | americanbankingnews.com
Sorrento Therapeutics (NASDAQ:SRNE) Research Coverage Started at StockNews.com
March 26, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
March 18, 2023 | wsj.com
Firm Retention Summary: Sorrento Therapeutics Inc.
March 15, 2023 | thestreet.com
Why Sorrento Therapeutics (SRNE) Stock Plummeted Today
March 2, 2023 | finance.yahoo.com
Is a Surprise Coming for Sorrento Therapeutics (SRNEQ) This Earnings Season?
February 27, 2023 | finance.yahoo.com
Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management
February 22, 2023 | benzinga.com
Why Sorrento Therapeutics Stock Is Soaring Today
March 26, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
February 22, 2023 | seekingalpha.com
Sorrento Therapeutics surges 28% as court nods for a $75M loan
February 21, 2023 | finance.yahoo.com
Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case
February 18, 2023 | finance.yahoo.com
Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)
February 17, 2023 | benzinga.com
Thinking about buying stock in Esports Entertainment, Marathon Digital, Sorrento Therapeutics, Nu Holdings, or ContextLogic?
February 15, 2023 | finance.yahoo.com
Why Kim Jong Un’s Daughter Is All Over North Korean Media
February 14, 2023 | finance.yahoo.com
Sorrento Therapeutics (SRNE) Loses -77.24% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
February 14, 2023 | uk.finance.yahoo.com
Sorrento Therapeutics Files For Bankruptcy
February 13, 2023 | seekingalpha.com
Hot Stocks: TDC climbs on earnings; FSLY upgrade; TWLO restructuring; SRNE bankruptcy
February 13, 2023 | wsj.com
Sorrento Therapeutics Files for Bankruptcy to Halt $173 Million Licensing Judgments
February 13, 2023 | proactiveinvestors.com
Sorrento Therapeutics stock plummets more than 60% on news of bankruptcy filing
February 13, 2023 | markets.businessinsider.com
Sorrento Therapeutics Stock Is Sinking: What's Going On?
February 13, 2023 | finance.yahoo.com
Sorrento Therapeutics Stock Nosedives After Filing Bankruptcy Paperwork
February 13, 2023 | finance.yahoo.com
Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.
February 13, 2023 | benzinga.com
Thinking about buying stock in Sorrento Therapeutics, Bed Bath & Beyond, C3.ai, Expion360, or SoundHound AI?
February 13, 2023 | msn.com
Sorrento sheds 60% after bankruptcy filing (update)
February 13, 2023 | finance.yahoo.com
A Sorrento Therapeutics, Inc. (NASDAQ:SRNE) insider increased their holdings by 2.0% last year
February 12, 2023 | finance.yahoo.com
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine
February 3, 2023 | wsj.com
Sorrento Issues Supplement to its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock
See More Headlines
Receive SRNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRNE Company Calendar

Today
3/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRNE
CUSIP
N/A
CIK
850261
Web
www.sorrentotherapeutics.com
Phone
(858) 203-4100
Fax
858-210-3759
Employees
799
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+3,576.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-428,330,000.00
Net Margins
-818.22%
Pretax Margin
-877.48%
Return on Equity
-282.82%
Return on Assets
-57.64%

Debt

Debt-to-Equity Ratio
0.14
Current Ratio
0.88
Quick Ratio
0.79

Sales & Book Value

Annual Sales
$60.32 million
Price / Sales
2.66
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.26 per share
Price / Book
1.31

Miscellaneous

Outstanding Shares
471,880,000
Free Float
459,611,000
Market Cap
$160.44 million
Optionable
Optionable
Beta
1.95

Social Links


Key Executives

  • Henry H. Ji
    Chairman, President & Chief Executive Officer
  • Shawn Sahebi
    Senior Vice President-Commercial Operations
  • Elizabeth Adkins Czerepak
    Chief Financial Officer & Executive Vice President
  • Mike A. Royal
    Chief Medical Officer
  • Robert D. Allen
    Senior Vice President-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SRNE Stock - Frequently Asked Questions

Should I buy or sell Sorrento Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRNE shares.
View SRNE analyst ratings or view top-rated stocks.

What is Sorrento Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued 1 year price targets for Sorrento Therapeutics' stock. Their SRNE share price forecasts range from $5.00 to $13.00. On average, they predict the company's share price to reach $9.00 in the next year. This suggests a possible upside of 2,547.1% from the stock's current price.
View analysts price targets for SRNE or view top-rated stocks among Wall Street analysts.

How have SRNE shares performed in 2023?

Sorrento Therapeutics' stock was trading at $0.8860 at the start of the year. Since then, SRNE stock has decreased by 61.6% and is now trading at $0.34.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Advanced Micro Devices (AMD), Moderna (MRNA), NVIDIA (NVDA), ADMA Biologics (ADMA), Tesla (TSLA), Dynavax Technologies (DVAX) and NIO (NIO).

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (1.89%), B. Riley Financial Inc. (1.11%), B. Riley Financial Inc. (1.11%), Charles Schwab Investment Management Inc. (0.74%), Norges Bank (0.66%) and JPMorgan Chase & Co. (0.66%). Insiders that own company stock include Henry Ji and Kim Janda.
View institutional ownership trends.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $0.34.

How much money does Sorrento Therapeutics make?

Sorrento Therapeutics (NASDAQ:SRNE) has a market capitalization of $160.44 million and generates $60.32 million in revenue each year.

How many employees does Sorrento Therapeutics have?

The company employs 799 workers across the globe.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The official website for the company is www.sorrentotherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 203-4100, via email at investors@sorrentotherapeutics.com, or via fax at 858-210-3759.

This page (NASDAQ:SRNE) was last updated on 3/26/2023 by MarketBeat.com Staff